Reducing Polycystic Liver Volume in ADPKD: Effects of Somatostatin Analogue Octreotide

Background and objectives: No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD). In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidne...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Caroli, Anna, Antiga, Luca, Cafaro, Mariateresa, Fasolini, Giorgio, Remuzzi, Andrea, Remuzzi, Giuseppe, Ruggenenti, Piero
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Nephrology 2010
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2863977/
https://ncbi.nlm.nih.gov/pubmed/20185596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.05380709
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak